TJPC(600488)2025-04-28 08:20Financial Performance - The company's revenue for Q1 2025 was CNY 785,765,994.13, a decrease of 9.03% compared to CNY 863,769,688.70 in the same period last year[4] - Net profit attributable to shareholders was CNY 58,050,125.92, showing a slight increase of 0.07% from CNY 58,012,016.03 year-on-year[4] - Total operating revenue for Q1 2025 was ¥785,765,994.13, a decrease of 9.05% compared to ¥863,769,688.70 in Q4 2024[19] - Net profit for Q1 2025 increased to ¥75,460,172.70, compared to ¥72,482,506.08 in Q4 2024, representing a growth of 3.93%[19] - The company’s total comprehensive income for the period was 75,907,038.19 RMB, compared to 73,365,945.30 RMB in the previous period, reflecting a growth of approximately 2.1%[20] - Basic and diluted earnings per share remained stable at 0.053 RMB per share for both Q1 2025 and Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -10,502,031.63, a decline of 120.37% compared to CNY 51,548,996.07 in the previous year, primarily due to an increase in accounts receivable and a decrease in sales collections[5] - In Q1 2025, the company reported a net cash flow from operating activities of -10,502,031.63 RMB, a decrease from 51,548,996.07 RMB in Q1 2024[22] - The company incurred total operating cash outflows of 637,404,364.07 RMB in Q1 2025, compared to 782,620,253.43 RMB in Q1 2024[23] - The net cash flow from financing activities was 128,961,037.93 RMB in Q1 2025, a significant improvement from -37,859,927.73 RMB in Q1 2024[24] - The company reported a decrease in cash inflows from operating activities, totaling 626,902,332.44 RMB in Q1 2025, down from 834,169,249.50 RMB in Q1 2024[23] - The cash and cash equivalents at the end of Q1 2025 increased to 702,801,334.96 RMB from 698,284,895.13 RMB at the end of Q1 2024[24] Assets and Liabilities - Total assets increased by 3.16% to CNY 5,878,076,844.70 from CNY 5,698,286,373.15 at the end of the previous year[4] - Total liabilities as of March 31, 2025, were ¥1,914,597,896.85, compared to ¥1,812,422,293.56 at the end of 2024, an increase of 5.67%[15] - The company's total assets reached ¥5,878,076,844.70 as of March 31, 2025, up from ¥5,698,286,373.15 at the end of 2024, an increase of 3.16%[14] - The company's equity attributable to shareholders increased to ¥3,117,551,908.66 as of March 31, 2025, compared to ¥3,057,347,087.18 at the end of 2024, a growth of 1.97%[15] Operational Developments - The company received approval for the raw material drug Fu-Ma-Suan-Fu-Mo-Tuo and the inhalation solution, which is expected to enhance its market presence and performance[10] - The company obtained approval from the Brazilian health authority for the raw material drug Dexamethasone Sodium Phosphate, facilitating market expansion in Brazil[10] - The company received its first production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities[10] - The company passed the FDA cGMP inspection, providing a solid foundation for further international market expansion[10] - The company completed the registration of Naloxone Hydrochloride Injection, enriching its product portfolio[10] - The company is managing a 55.5222% stake in Tianjin Xinda Pharmaceutical Co., Ltd., enhancing its strategic investments[11] Inventory and Receivables - Accounts receivable increased to ¥426,084,165.89 in Q1 2025, compared to ¥291,238,382.36 in Q4 2024, marking a significant rise of 46.2%[13] - Inventory levels were reported at ¥665,055,904.34 as of March 31, 2025, slightly up from ¥651,915,382.71 at the end of 2024, an increase of 2.0%[13] - Short-term borrowings increased to ¥125,711,648.86 in Q1 2025 from ¥108,576,306.93 in Q4 2024, reflecting a rise of 15.5%[14]